Cochrane · systematic review · CD011640
Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD)
Lombardi, R, Onali, S, Thorburn, D, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
9
No studies
3
Included studies
NR
No studies 3 · 25%Ungraded 0 · 0%Very low 9 · 75%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antioxidants versus no intervention for non‐alcohol related fatty liver disease
Population: participants with non‐alcohol related fatty liver disease (NAFLD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Antioxidants vs no intervention | no estimate extracted | 1 study · 87 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Antioxidants vs no intervention | no estimate extracted | 1 study · 87 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Antioxidants vs no intervention | rate ratio 0.89 [0.36, 2.19] | 2 studies · 254 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Antioxidants vs no intervention | no estimate extracted | NR | No studies |
Bile acids versus no intervention for non‐alcohol related fatty liver disease
Population: participants with non‐alcohol related fatty liver disease (NAFLD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Bile acids vs no intervention | OR 5.11 [0.24, 107.34] | 4 studies · 659 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Bile acids vs no intervention | OR 1.56 [0.84, 2.88] | 3 studies · 404 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Bile acids vs no intervention | Rate ratio 1.01 [0.66, 1.54] | 3 studies · 404 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Bile acids vs no intervention | no estimate extracted | NR | No studies |
Thiazolidinediones versus no intervention for non‐alcohol related fatty liver disease
Population: participants with non‐alcohol related fatty liver disease (NAFLD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Thiazolidinediones vs no intervention | no estimate extracted | 1 study · 74 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Thiazolidinediones vs no intervention | no estimate extracted | 2 studies · 194 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Thiazolidinediones vs no intervention | rate ratio 0.25 [0.06, 1.05] | 3 studies · 357 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Thiazolidinediones vs no intervention | no estimate extracted | NR | No studies |